Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Phio Pharmaceuticals ( (PHIO) ).
On September 3, 2025, Phio Pharmaceuticals announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference, scheduled for September 8-10, 2025. The company also reported progress in its Phase 1b clinical trial for skin cancer, with patients now being treated in the 5th cohort. This advancement marks a significant step in the development of their lead product candidate, PH-762, which could potentially offer a non-surgical treatment option for skin cancers.
The most recent analyst rating on (PHIO) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Phio Pharmaceuticals stock, see the PHIO Stock Forecast page.
Spark’s Take on PHIO Stock
According to Spark, TipRanks’ AI Analyst, PHIO is a Neutral.
Phio Pharmaceuticals is struggling financially, with no revenue and consistent losses, significantly impacting its stock score. The technical indicators show mixed signals, with some short-term momentum but bearish long-term trends. The valuation is speculative due to negative earnings. The recent board appointment is a positive corporate event but has limited impact on overall financial health.
To see Spark’s full report on PHIO stock, click here.
More about Phio Pharmaceuticals
Phio Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company specializing in siRNA gene silencing technology aimed at immuno-oncology therapeutics. Their INTASYL compounds are designed to enhance immune cells’ ability to combat cancer, with their lead program, PH-762, targeting the PD-1 gene in various skin cancers.
Average Trading Volume: 1,140,840
Technical Sentiment Signal: Sell
Current Market Cap: $11.28M
For an in-depth examination of PHIO stock, go to TipRanks’ Overview page.